| Literature DB >> 33465052 |
Verónica Miguel1, Jessica Tituaña1, J Ignacio Herrero1, Laura Herrero2,3, Dolors Serra2,3, Paula Cuevas4, Coral Barbas4, Diego Rodríguez Puyol5, Laura Márquez-Expósito6, Marta Ruiz-Ortega6, Carolina Castillo7, Xin Sheng8, Katalin Susztak8, Miguel Ruiz-Canela9,10, Jordi Salas-Salvadó10,11, Miguel A Martínez González9,10, Sagrario Ortega12, Ricardo Ramos13, Santiago Lamas1.
Abstract
Chronic kidney disease (CKD) remains a major epidemiological, clinical, and biomedical challenge. During CKD, renal tubular epithelial cells (TECs) present a persistent inflammatory and profibrotic response. Fatty acid oxidation (FAO), the main source of energy for TECs, is reduced in kidney fibrosis and contributes to its pathogenesis. To determine whether gain of function in FAO (FAO-GOF) could protect from fibrosis, we generated a conditional transgenic mouse model with overexpression of the fatty acid shuttling enzyme carnitine palmitoyl-transferase 1A (CPT1A) in TECs. Cpt1a-knockin (CPT1A-KI) mice subjected to 3 models of renal fibrosis (unilateral ureteral obstruction, folic acid nephropathy [FAN], and adenine-induced nephrotoxicity) exhibited decreased expression of fibrotic markers, a blunted proinflammatory response, and reduced epithelial cell damage and macrophage influx. Protection from fibrosis was also observed when Cpt1a overexpression was induced after FAN. FAO-GOF restored oxidative metabolism and mitochondrial number and enhanced bioenergetics, increasing palmitate oxidation and ATP levels, changes that were also recapitulated in TECs exposed to profibrotic stimuli. Studies in patients showed decreased CPT1 levels and increased accumulation of short- and middle-chain acylcarnitines, reflecting impaired FAO in human CKD. We propose that strategies based on FAO-GOF may constitute powerful alternatives to combat fibrosis inherent to CKD.Entities:
Keywords: Chronic kidney disease; Fatty acid oxidation; Fibrosis; Nephrology
Year: 2021 PMID: 33465052 PMCID: PMC7919728 DOI: 10.1172/JCI140695
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808